VistaGen Therapeutics (VTGN) Receives a Buy from Maxim Group


In a report issued on July 9, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN), with a price target of $4. The company’s shares closed yesterday at $0.67, close to its 52-week low of $0.52.

According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -18.4% and a 26.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VistaGen Therapeutics with a $4 average price target.

See today’s analyst top recommended stocks >>

Based on VistaGen Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.72 million. In comparison, last year the company had a GAAP net loss of $4.21 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts